- The Manipal Hospitals IPO is a ₹ 9,275 crore issue with ₹ 8,000 crore of fresh capital, mainly to repay debt taken for the Sahyadri acquisition.
- The valuation is described as richly priced: at the upper band of ₹ 590, it trades at 70 times earnings, and for every ₹ 100 invested the business earns about ₹ 1.40 a year.
- Manipal's operational strengths include rising revenue per occupied bed (from ₹ 61,742 to ₹ 68,938), the industry's fastest bed turnover (2.8 days average stay), and improved margins at earlier acquisitions like Columbia Asia and AMRI.
- The bed count flatters: of 13,037 licensed beds, 3,785 are not owned by Manipal, leaving 9,252 owned licensed beds and roughly 6,900 open on a full-year basis.
- Manipal has the lowest occupancy among leaders at 64.5 per cent, and acquired Sahyadri is running at 62 per cent occupancy while losing ₹ 41 crore after tax in the six months Manipal owned it.
- Goodwill of ₹ 8,121 crore is close to half of post-issue net worth, and Manipal has previously written off ₹ 114 crore on its HealthMap diagnostics arm.
- Of the ₹ 8,000 crore raised, ₹ 5,553 crore redeems Sahyadri debentures and ₹ 574 crore buys out minority shareholders, leaving under ₹ 1,900 crore for expansion.
- The verdict is that Manipal asks about 80 times last year's profit (70 times after adjustments), so investors are buying the assumption that Sahyadri will be fixed, occupancy will rise, and goodwill will hold.
Manipal Health Enterprises is in the spotlight with its initial public offering (IPO) aiming to raise ₹9,275 crore, primarily to address ₹5,310 crore of debt incurred from acquiring the Sahyadri hospital chain. The IPO is priced at ₹590 per share, equating to 70 times earnings, raising questions about its valuation.123451112171819
The company operates 13,037 licensed beds, but only 9,252 are owned, with 6,900 actively treating patients. Its occupancy rate stands at 64.5%, lower than competitors like Apollo and Fortis. Sahyadri, acquired for ₹5,841 crore, is currently underperforming with 62% occupancy and a revenue per bed significantly below the group average.910
Investors are advised to consider waiting for key indicators such as falling interest costs, improved occupancy rates, and better revenue performance from Sahyadri before committing. The IPO's pricing reflects not just current performance but also future expectations of recovery and growth in the healthcare sector.
“You are not buying today's numbers. You are buying the assumption that Sahyadri will be fixed,” analysts suggest, emphasizing the need for tangible improvements before investing.
The funds raised will primarily be used to redeem Sahyadri's debentures and buy out minority shareholders, leaving limited capital for future expansions, which include plans for new hospitals in Mumbai and Pune.
“The ₹9,275 crore issue, with ₹8,000 crore of fresh capital, is mainly meant to repay the ₹5,310 crore debt from the Sahyadri acquisition. At the upper band of ₹590, the offer trades at 70 times earnings, with the business earning about ₹1.40 per ₹100 invested.”
Value Research
